An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Olopatadine Hydrochloride; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Subjects must provide written consent.

• Subjects must have a diagnosis of allergic conjunctivitis.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Itching and/or hyperemia associated with diseases other than allergic conjunctivitis.

• Retinal detachment, diabetic retinopathy, or any progressive disease in posterior segment of the eye.

• Known history of ocular infection.

• Contact lens wear during study.

• Pregnant, nursing.

• Participation in another clinical study within 30 days of Informed Consent.

• Other protocol-defined exclusion criteria may apply.